*Due to changes in REB membership, many past lists are available. Please contact email@example.com for any past lists that you may require.
Release of Funds prior to REB Review
Industry Funded Research Fee Schedule
- Ethics Review of Industry Funded Research (Full Board Review) - $3 000.00
Ontario Cancer Research Ethics Board (OCREB) Protocols
The University of Western Ontario and the Lawson Health Research Institute (LHRI) are committed to ensuring that cancer patients attending London hospitals have the opportunity to participate in multi-centred, time sensitive, competitive enrollment cancer clinical trials. In an effort to facilitate this process, The University of Western Ontario and the Lawson Health Research Institute have agreed to sanction the use of the Ontario Cancer Research Ethics Board (OCREB) in lieu of Western’s Health Sciences Research Ethics Board (HSREB).
- The acceptance of OCREB as an alternate research ethics board is limited to the ethical review of new multi-centre cancer clinical trials where the study sponsor has identified OCREB as the preferred research ethics board provincially; and, where Western and/or LHRI investigators are leading and/or participating in these trials. All other types of research previously approved by OCRE B must still obtain approval from Western’s HSREB. E.g. epidemiological, tissue use, non-clinical.
- Ongoing cancer clinical trials currently under review by, or approved by, Western’s HSREB will remain under the jurisdiction of Western’s HSREB until the completion of the trial.
- The University of Western Ontario and the Lawson Health Research Institute retain the right to require ethical approval from Western’s HSREB for studies previously approved by OCREB if, in their opinion, circumstances warrant it.
- Western’s Health Sciences Research Ethics Board accepts no responsibility for the conduct of research conducted under the auspices of OCREB, for which Western’s HSREB has not issued an approval notice.
Further reading: OCREB Guidelines